OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Liu on SBRT and IMRT in Colorectal Cancer

March 20th 2025

Yufei Liu, MD, PhD, discusses SBRT and IMRT strategies and the role of radiation in patients with colorectal cancer.

Dr Bhat on the Influence of MPN Risk Stratification on Treatment Decision-Making

March 20th 2025

Seema A. Bhat, MD, discusses typical treatment decisions for patients with myeloproliferative neoplasms based on risk stratification.

Dr Randall on Factors Influencing the Choice Between Systemic Therapy and Surgery in TGCT

March 20th 2025

R. Lor Randall, MD, FACS, discusses how to select between vimseltinib, pexidartinib, and surgery for patients with tenosynovial giant cell tumor.

Moyer on Early Efficacy Data With Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

March 19th 2025

Jacob Moyer, BS, discusses early, real-world efficacy and safety data with nadofaragene firadenovec in BCG-unresponsive non–muscle-invasive bladder cancer.

Dr Garfall on the Inclusion Criteria for a Study Evaluating Ide-Cel in Myeloma After Suboptimal Transplant/Maintenance Response

March 19th 2025

Alfred L. Garfall, MD, describes the inclusion criteria for a phase 2 study evaluating ide-cel as first-line maintenance in multiple myeloma.

Dr Coombs on the Need for Consensus to Define High-Risk CLL

March 19th 2025

Catherine C. Coombs, MD, discusses the need to establish a standardized definition of high-risk CLL.

Dr Fakih on the Future of Botensilimab and Balstilimab–Based Therapies in MSS mCRC

March 18th 2025

Marwan Fakih, MD, discusses the advancement of botensilimab/balstilimab–based combination therapies in microsatellite-stable colorectal cancer.

Dr Montero on the Rationale for Evaluating Zanidatamab/Evorpacept in HER2+ Metastatic Breast Cancer

March 18th 2025

Alberto Montero, MD, MBA, CPHQ, explains the rationale for evaluating zanidatamab plus evorpacept in HER2-expressing metastatic breast cancer.

Dr Lee on the Antitumor Activity of Rinatabart Sesutecan in FRα+ Platinum-Resistant Ovarian Cancer

March 18th 2025

Elizabeth Lee, MD, discusses the efficacy of rinatabart sesutecan in patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

Dr Lantsman on the Real-World Safety and Efficacy of Dostarlimab Plus Chemo in Endometrial Cancer

March 18th 2025

Taliya Lantsman, MD, discusses real-world safety and efficacy data with dostarlimab plus chemotherapy in patients with advanced endometrial cancer.

Dr Alencar on Unmet Needs Associated With BTK Inhibitor Resistance in CLL

March 17th 2025

Alvaro Alencar, MD, discusses current unmet needs following the development of covalent BTK inhibitor resistance in CLL.

Dr Sheen on Racial Disparities in Physiology, Genetic Testing in Breast Cancer

March 17th 2025

Melanie A. Sheen, MD, discusses a study aimed at determining differences in breast composition and assess racial disparities in access to and utilization of genetic counseling.

Dr Herrmann on Assessing Time Toxicity in Lung Cancer Trials

March 17th 2025

Amanda Herrmann, MD, discusses findings from the TIME-TOX Lung study, which retrospectively assessed the time toxicity associated with lung cancer clinical trials.

Dr Rampal on ​Emerging Therapies Under Investigation in Myelofibrosis

March 17th 2025

Raajit Rampal, MD, discusses the variety of agents in phase 3 trials for the treatment of patients with myelofibrosis.

Dr Westin on PFS Benefit With DUO-E Regimen Across Histologic and Molecular pMMR Endometrial Cancer Subgroups

March 17th 2025

Shannon Westin, MD, MPH, FACOG, discusses the efficacy of durvalumab plus chemotherapy and olaparib in pMMR recurrent endometrial cancer.

Dr Silverstein on the Efficacy of Abemaciclib Plus Hormonal Therapy in Recurrent Low- or High-Grade Serous Ovarian Cancer

March 17th 2025

Jordyn Silverstein, MD, discusses the efficacy of abemaciclib plus hormonal therapy in recurrent ovarian cancer or endometroid endometrial cancer.

Dr Grisham on the Efficacy of Avutometinib Plus Defactinib in Gynecologic Mesonephric Cancer

March 16th 2025

Rachel N. Grisham, MD, discusses the efficacy of avutometinib plus defactinib in patients with advanced or recurrent gynecologic mesonephric cancer.

Dr Van Gorp on the Long-Term Efficacy of Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer

March 16th 2025

Toon Van Gorp, MD, PhD, discusses the efficacy of mirvetuximab soravtansine in FRα-positive platinum-resistant ovarian cancer after 30.5 months of follow-up.

Dr Richter on Goals for Expanding T-Cell–Redirecting Therapies in Myeloma

March 14th 2025

Joshua Richter, MD, discusses the evolution of multiple myeloma treatment in recognition of Myeloma Awareness Month 2025.

Dr Koehne on ​the Evolution of the Multiple Myeloma Treatment Paradigm

March 14th 2025

Guenther Koehne, MD, discusses the roles of ASCT, CAR T-cell therapy, and bispecific antibodies in the treatment of patients with multiple myeloma.

NEXT PAGE
PREVIOUS PAGE